Neuralink to Launch Human Blindsight Trials Next Year

The company plans to begin human implantation of its visual restoration device within the next 6 to 12 months.

Updated on Oct. 24, 2026 in Stroke

Neuralink to Launch Human Blindsight Trials Next Year

Live Poll

Is now the right time to begin human trials for experimental sight-restoring brain implants?

Neuralink expects to perform its first human Blindsight implants between April and October 2026. This technology aims to restore visual perception by directly stimulating the visual cortex.

Why it matters

The device is specifically designed for individuals who cannot benefit from traditional retinal or optic-nerve solutions. It represents a shift toward using direct brain-computer interfaces to restore sensory function.

The FDA granted the Blindsight device Breakthrough Device Designation on September 17, 2024. As of January 2026, 21 participants have received the company's separate N1 motor-control implant.

The players

Neuralink

This neurotechnology company is developing implantable brain-computer interfaces intended to connect human brains with computers.

Elon Musk

He is the founder of Neuralink and frequently announces the company's timelines for clinical development and human testing.

The details

Blindsight functions as a write-interface, transmitting data into the brain to generate artificial sight. Early visual resolution from the device is expected to resemble graphics from early Nintendo or Atari consoles.

September 17, 2024: Device received FDA Breakthrough Device Designation
Mid-2025: Monkey completed three years of long-term implant testing
January 28, 2026: 21 patients received N1 motor-control implants
August 4, 2026: Musk announced human implants planned within 6-12 months
October 2026: Article published regarding Blindsight device timeline

The Big Picture

The Blindsight project follows the established pattern of companies utilizing the FDA Breakthrough Device Designation to expedite clinical progress for complex neural interfaces.

This development offers a potential future treatment path for individuals with permanent vision loss who are currently ineligible for other medical interventions. Patients should monitor clinical registry updates to determine future eligibility criteria for human trials.

The takeaway

Early results suggest that initial visual restoration may provide low-resolution images rather than full sight. Ongoing long-term testing in animal models remains critical for evaluating the safety and long-term viability of the hardware before widespread adoption.